Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB521 + Ivonescimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB521 | AB-521|AB 521|casdatifan | HIF2A Inhibitor 6 | AB521 selectively inhibits HIF-2alpha, potentially resulting in downregulation of HIF-2alpha target genes and antitumor activity (Ann Oncol 33 (2022): S21). | |
| Ivonescimab | AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 141 VEGFA Antibody 6 | Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05536141 | Phase I | AB521 + Axitinib + Zimberelimab AB521 + Ivonescimab AB521 + Tivozanib AB521 AB521 + Cabozantinib AB521 + Zimberelimab AB521 + Ipilimumab + Zimberelimab | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) | Recruiting | USA | ESP | AUS | 1 |